Want to see PL:CLN full AI Analyst Report?
Celon Pharma SA (CLN) Stock Statistics & Valuation Metrics
Total Valuation
Celon Pharma SA has a market cap or net worth of PLN 921.89M. The enterprise value is PLN 1.07B.
- Market Cap
- PLN 921.89M
- Enterprise Value
- PLN 1.07B
Share Statistics
Celon Pharma SA has 53,911,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 53,911,500
- Owned by Insiders
- ―
- Owned by Institutions
- 0.22%
Financial Efficiency
Celon Pharma SA’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -14.09%.
- Return on Equity (ROE)
- -0.22
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -14.09%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 374.64K
- Profits Per Employee
- -141.72K
- Employee Count
- 560
- Asset Turnover
- 0.46
- Inventory Turnover
- 9.55
Valuation Ratios
The current PE Ratio of Celon Pharma SA is 8.14. Celon Pharma SA’s PEG ratio is 0.18.
- PE Ratio
- 8.14
- PS Ratio
- 4.25
- PB Ratio
- 1.85
- Price to FCF
- -16.28
- Price to Operating Cash Flow
- 33.78
- PEG Ratio
- 0.18
Income Statement
In the last 12 months, Celon Pharma SA had revenue of 209.80M and earned -79.36M in profits. Earnings per share was -1.47.
- Revenue
- 209.80M
- Gross Profit
- -39.48M
- Operating Income
- -56.76M
- Pretax Income
- -58.97M
- Net Income
- -79.36M
- EBITDA
- -10.48M
- Earnings Per Share (EPS)
- -1.47
Cash Flow
In the last 12 months, operating cash flow was 27.29M and capital expenditures -83.92M, giving a free cash flow of -56.63M billion.
- Operating Cash Flow
- 27.29M
- Free Cash Flow
- -56.63M
- Free Cash Flow per Share
- -1.05
Dividends & Yields
Celon Pharma SA pays an annual dividend of PLN 0.30, resulting in a dividend yield of ―
- Dividend Per Share
- PLN 0.30
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.14%
- Earnings Yield
- 12.02%
Stock Price Statistics
- Beta
- 0.56
- 52-Week Price Change
- -20.83%
- 50-Day Moving Average
- 20.22
- 200-Day Moving Average
- 20.82
- Relative Strength Index (RSI)
- 28.10
- Average Volume (3m)
- 19.66K
Important Dates
Celon Pharma SA upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 16, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- Jun 27, 2024
Financial Position
Celon Pharma SA as a current ratio of 1.62, with Debt / Equity ratio of 5.21%
- Current Ratio
- 1.62
- Quick Ratio
- 1.20
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.04
- Interest Coverage Ratio
- -35.54
Taxes
In the past 12 months, Celon Pharma SA has paid 20.40M in taxes.
- Income Tax
- 20.40M
- Effective Tax Rate
- -0.35
Enterprise Valuation
Celon Pharma SA EV to EBITDA ratio is 123.16, with an EV/FCF ratio of -17.95.
- EV to Sales
- 4.69
- EV to EBITDA
- 123.16
- EV to Free Cash Flow
- -17.95
- EV to Operating Cash Flow
- 37.26
Balance Sheet
Celon Pharma SA has PLN 34.53M in cash and marketable securities with PLN 128.44M in debt, giving a net cash position of -PLN 93.91M billion.
- Cash & Marketable Securities
- PLN 34.53M
- Total Debt
- PLN 128.44M
- Net Cash
- -PLN 93.91M
- Net Cash Per Share
- -PLN 1.74
- Tangible Book Value Per Share
- PLN 8.78
Margins
Gross margin is 6.76%, with operating margin of -11.78%, and net profit margin of 51.08%.
- Gross Margin
- 6.76%
- Operating Margin
- -11.78%
- Pretax Margin
- 66.23%
- Net Profit Margin
- 51.08%
- EBITDA Margin
- 3.81%
- EBIT Margin
- -16.05%
Scores
- Smart Score
- ―
- AI Score
- 46